¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Drug design and discovery."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • drug addiction
    ¾à¹°Áßµ¶, ¾à¹°Å½´Ð
  • drug adjuvant
    ¾à¹°º¸Á¶Á¦, º¸Á¶¾à¹°
  • drug adsorption
    ¾à¹°ÈíÂø
  • drug allergy
    ¾à¹°¾Ë·¹¸£±â
  • drug delivery system
    ¾à¹°Àü´Þü°è
  • drug dependence
    ¾à¹°ÀÇÁ¸
  • drug dispensing
    ¾à¹°Á¶Á¦
  • drug eruption
    ¾à¹°¹ßÁø, ¾àÁø
  • drug idiosyncrasy
    ¾à¹°Æ¯ÀÌüÁú
  • drug interaction
    ¾à¹°»óÈ£ÀÛ¿ë
  • drug interference
    ¾à¹°°£¼·
  • drug intoxication
    ¾à¹°Áßµ¶
  • drug level monitoring
    ¾à¹°³óµµ°¨½Ã, ¾à¹°³óµµÃøÁ¤
  • drug of choice
    ÀÏÂ÷¼±Åþà
  • drug overdose
    1. ¾à¹°°ú·®Åõ¿© 2. ¾à¹°°ú·®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • autonomic drug
    ÀÚÀ²½Å°æ¾à
  • awaking drug control law
    °¢¼ºÁ¦Á¶Àý¹ý
  • drug abstinence
    ¾à¹°±Ý´Ü, ±Ý´Ü
  • drug abuse
    ¾à¹°³²¿ë
  • drug acne
    ¾à¹°¿©µå¸§
  • drug addiction
    ¾à¹°Áßµ¶
  • drug adjuvant
    ÀǾàǰ÷°¡¹°
  • drug adsorption
    ¾à¹°ÈíÂø
  • drug allergy
    ¾à¹°¾Ë·¹¸£±â
  • drug-induced hemolytic anemia
    ¾à¹°À¯¹ß¿ëÇ÷ºóÇ÷
  • new drug application
    ½Å¾àÇã°¡½Åû
  • drug resistant bacterium
    ¾àÁ¦³»¼º±Õ
  • chemotherapeutic drug monitoring
    È­Çпä¹ý¾àÁ¦°¨½Ã
  • cognitive-acting drug
    ÀÎÁö±â´ÉȰ¼ºÁ¦
  • common drug
    º¸Åë¾à
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • antimuscarinic drug
    Ç×¹«½ºÄ«¸°Á¦, Ç×¹«½ºÄ«¸°(¼º)¾à
  • antiobestic drug
    »ìºüÁü¾à, Ç׺ñ¸¸¾à (ù÷ÝþØ»å·).
  • antiplatelet drug
    Ç×Ç÷¼ÒÆÇ¾à.
  • antipruritic drug
    Ç×¼Ò¾ç¾à£¬Áø¾ç¾à(òååÊå·), °¡·Á¿òÁ¦Áö¾à.
  • antipsychotic drug
    Ç×Á¤½Åº´¾à(ù÷ïñãêÜ»å·).
  • antipsychotic drug
    Ç×Á¤½Åº´¾à
  • antipyretic drug
    ÇØ¿­¾à(ú°æðå·).
  • antiseborrheic drug
    Ç×Áö·ç¾à(¡­å·).
  • antiseizure drug
    Ç×°æ·Ã¾à(ù÷ÌâÕýå·).
  • antiseptic drug
    ¹æºÎ¾à(¡­¾à).
  • antispirochetal drug
    Ç×½ºÇÇ·ÎÇ쟾à.
  • antispirochetic drug
    Ç×½ºÇÇ·ÎÇ쟾à.
  • antithyroid drug
    Ç×°©»ó¼±¾à(¡­å·).
  • antituberculosis drug
    Ç×°áÇÙ¾à(Á¦)
  • antiviral agent =a. drug
    Ç×¹ÙÀÌ·¯½º¾à, Ç×¹ÙÀÌ·¯½º¹°Áú, Ç×¹ÙÀÌ·¯½ºÀÎÀÚ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • hand foot and mouth disease
    ¼Õ¹ßÀÔº´ (¡­Ü»), ¼öÁ·±¸º´(â¢ðëϢܻ)
  • heat and acetic acid test
    °¡¿Â¾Æ¼¼Æ®»ê½ÃÇè (¹ý)(ʥ计­ß«ãËúÐÛö).
  • hereditary motor and sensory neuropathy
    À¯Àü¼º¿îµ¿ °¨°¢½Å°æº´Áõ
  • hunger and thirst treatment
    ±â°¥¿ä¹ý.
  • incision and drainage
    Àý°³¹è³ó(ü°³¹è³ó).
  • inflammation,vascular flow and caliber
    Ç÷°üÇ÷·ù(úìηúì×µ)¿Í±¸°æ(Ï¢ÌÓ)
  • insect bites and stings
    °ïÃæ±³»ó(ÍàõùÎáß¿)¹× ÀÚ»ó(í©ß¿)
  • intake and output record
    ¼·Ãë¿Í ¹è¼³·® ±â·Ï.
  • international commission on radiation units and me
    asurements (ICRU)
  • jejunal and ileal veins <³ª> venae jejunales et ilei
    °øÈ¸ÀåÁ¤¸Æ(°øÈ¸ÀåÁ¤¸Æ).
  • jejunal and ileal veins ³ª venae jejunales et ilei
    °øÈ¸ÀåÁ¤¸Æ(Íöüß ð¡Øæ).
  • kidney ureter and bladder =KUB
    ½Å-´¢°ü-¹æ±¤ ´Ü¼øÃÔ¿µ
  • lateral cord and associated anterior cornual syndrome
    Ãø»èµ¿ÃøÀü°¢ÁõÈıº (ö°ßãÔÒö°îñÊÇñøý¦ÏØ).
  • law for control of poisonous and powerful agents
    µ¶±Ø¹°Ãëü¹ý(ËÄË»ËŅ̬̃ ËÑ).
  • law of weights and measures
    °è·®¹ý(Ë­ËâËÑ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
ADM abductor digiti minimi; administrative medicine; admission; Adriamycin; Alcohol, Drug Abuse and Ment...
FD&C Food, Drug and Cosmetic Act; food, drugs, and cosmetics
ADAMHA Alcohol, Drug Abuse, and Mental Health Administration
ADDU alcohol and drug dependence unit
ADME [drug] absorption, distribution, metabolism, and excretion
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
DIC Drug Information Center
DRP Drug Related Problems
D.U.E. Drug Use Evaluation
DUR Drug Use Review
DUR Drug Utilization Review
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • safety regulation and standard
    ¾ÈÀü Á¶Àý ¹× Ç¥ÁØ
  • salt and pepper appearance
    ¼Ò±Ý ÈÄÃß°¡·ç ¸ð¾ç
  • scalel handles and blade
    ¿Ü°ú¿ë Ä®
    ¿Ü°úÀû Àý°³¸¦ À§ÇØ »ç¿ëµÇ´Â Ä®·Î ÁÖ·Î 3¹ø Ä®´ë¿Í 15¹ø Ä®³¯À» »ç¿ëÇÑ´Ù.
  • separation of child and parents
    Áø·á ÁßÀÇ ¸ðÀÚ ºÐ¸®
  • signs and symptoms
    ¡ÈÄ¿Í Áõ»ó
  • spatial and temporal
    ½Ã°ø
  • subepithelial deposit and sclerosis
    »óÇÇÇÏ ÃàÀû°ú °æÈ­
  • superior and inferior lobe
    »ó ¹× ÇÏ¿±
  • supportive and symptomatic therapy
    Áõ»ó ¿ä¹ý
  • synovial bursae and sheaths
    À±È° ÁÖ¸Ó´Ï ¹× À±È°Áý
  • through-and-through drain
    °üÅë ¹è³ó°ü
  • to and fro absorbent system
    ¿Õº¹ Èí¼ö¹ý
  • to and fro flow
    ÀüÈÄ À¯µ¿
  • to and fro sound
    ¸¶ÂûÀ½
  • upright and relaxed position
    Á¤ÁÂÀ§ÀÇ ÀÌ¿ÏµÈ ÀÚ¼¼
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
drug, anti-infective A medication capable of acting against infection, by inhibiting the spread of an infectious agent or by killing the infectious agent outright.
(12 Dec 1998)
drug approval Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug.
(12 Dec 1998)
drug carriers Substances that facilitate time-controlled delivery, organ-specific targeting, protection, prolonged in vivo function, and decrease of toxicity of drugs. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers.
(12 Dec 1998)
drug combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. It is differentiated from drug therapy, combination in which two or more drugs are administered separately for a combined effect.
(12 Dec 1998)
drug compounding The preparation, mixing, and assembling of a drug.
(12 Dec 1998)
drug costs The amount that a health care institution or organization pays for its drugs. It is one component of the final price that is charged to the consumer (fees, pharmaceutical or prescription fees).
(12 Dec 1998)
drug delivery The method and route used to provide medication.
(16 Dec 1997)
drug delivery systems Systems of administering drugs through controlled delivery so that an optimum amount reaches the target site. Drug delivery systems encompass the carrier, route, and target.
(12 Dec 1998)
drug dependence Use of a drug for a reason other than which it was intended or in a manner or in quantities other than directed. Drug dependence is a compulsion to take a drug to produce a desired effect or prevent unpleasant effects when the drug is withheld. Risk factors for drug abuse include: low self esteem, inability to deal with stress and emotional instability. Juveniles use drugs due to peer pressure. Signs of drug use in children include: a change in friends or group, long absences from home, poor performance in school, seclusion, stealing, lying, criminal behaviour, deteriorating family relationships, signs of drug intoxication and changes in behaviour. Commonly abused drugs include narcotic analgesic agents, benzodiazepines, cocaine, amphetamines, barbiturates, marijuana, LSD and phencyclidine. Many labs now offer quick and inexpensive urine drug screening. Psychological counseling and parental support will be necessary in children with this problem.
(27 Sep 1997)
drug development pathway The various procedures and studies that must be undertaken to satisfy Food and Drug Administration requirements for drug approval and marketing.
(14 Nov 1997)
drug eruptions Adverse cutaneous reactions caused by ingestion, parenteral use, or local application of a drug. These may assume various morphologic patterns and produce various types of lesions.
(12 Dec 1998)
drug evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.
(12 Dec 1998)
drug-fast Pertaining to microorganisms that resist or become tolerant to an antibacterial agent.
(05 Mar 2000)
drug fever Fever resulting from an allergic reaction to a drug that clears rapidly on discontinuation of the drug.
(05 Mar 2000)
drug half-life The amount of time it takes for one-half of an administered drug to be lost through biological processes (metabolism and elimination).
(27 Sep 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • Daphnis and Chloe
    ´ÙÇÁ´Ï½º¿Í Ŭ·Î¿¡(2-3¼¼±â°æ ±×¸®½ºÀÇ ¸ñ°¡ÀûÀÎ À̾߱⠼ÓÀÇ ¼øÁøÇÑ ¿¬Àεé)
  • Darby and Joan
    (¹Î¿äÁßÀÇ ³ëºÎºÎ¿¡¼­);ÀÇÁÁÀº ´ÄÀº ºÎºÎ
  • Dark and Bloody Ground
    (¹Ì)KentuckyÁÖÀÇ º°¸í(ÃʱâÀÇ Àεð¾ð°úÀÇ ÀüÅõ¿Í °ü·ÃµÈ ȣĪ)
  • E.and P.
    extraordinary and plenipotentiary Ư¸í Àü±ÇÀÇ
  • Economic and Social Council
    =ECOSOC
  • Food and Agriculture Organization
    (À¯¿£) ½Ä·® ³ó¾÷ ±â±¸
  • Foreign and Commonwealth Office
    ¿Ü¹« ¿¬¹æ¼º
  • Gog and Magog
    °î°ú ¸¶°î(»çÅÁ¿¡ ¹ÌȤµÇ¾î ÇÏ´Ã ³ª¶ó¿¡ ´ëÇ×ÇÏ´Â µÎ³ª¶ó)
  • H and C
    Çì·ÎÀÎ(heroin)°ú ÄÚÄ«ÀÎ(cocaine)À» ¼¯Àº °Í
  • Hereford and Worcester
    À×±Û·£µå ¼­ºÎÀÇ ÁÖ(1974³â ½Å¼³)
  • International Bank for Reconstruction and Development
    ±¹Á¦ ºÎÈï°³¹ßÀºÇà(IBRD)ÅëĪ(the world bank)
  • Jekyll and Hyde
    2ÁßÀΰÝÀÚÀÇ;2Áß ÀΰÝÀûÀÎ
  • Punch and Judy
    Àͻ콺·¯¿î ¿µ±¹ÀÇ ÀÎÇü±Ø
  • R&D,R.and D.
    research and development ¿¬±¸ °³¹ß
  • Royal and Ancient
    ·Î¿­ ¾Øµå ¿¡ÀÎ¼ÇÆ® °ñÇÁ Ŭ·´(¼¼°è ÃÖ°í,1754³â °³¼³)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á